Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Guerci

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
BMJ Open|January 29, 2026
Psychosocial burden in type 1 diabetes: a cross-sectional network analysis in the SFDT1 studyGloria A Aguayo, Vincent P Martin, Dulce Canha, et al.
Diabetes, Obesity & Metabolism|September 13, 2023
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomesFrancesco Giorgino, Bruno Guerci, Martin Füchtenbusch, et al.
BMJ (Clinical Research Ed.)|February 29, 2012
Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetesAndrew J Farmer, Rafael Perera, Alison Ward, et al.
Diabetes, Obesity & Metabolism|March 10, 2026
Economic burden of type 2 diabetes management in France according to clinical characteristicsBruno Guerci, Christèle Blanc-Bisson, Eric Vicaut, et al.
Diabetes Care|May 26, 2016
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 TrialJulio Rosenstock, Bruno Guerci, Markolf Hanefeld, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 4, 2020
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported OutcomesKristina S Boye, Hélène Sapin, Luis-Emilio García-Pérez, et al.
Diabetes Technology & Therapeutics|April 8, 2011
A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patientsPauline Schaepelynck, Eric Renard, Nathalie Jeandidier, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 7, 2021
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline CharacteristicsLuis-Emilio García-Pérez, Kristina S Boye, Myriam Rosilio, et al.
Journal of Diabetes and Its Complications|May 17, 2017
Urinary lysophopholipids are increased in diabetic patients with nephropathyJean-Sébastien Saulnier-Blache, Eva Feigerlova, Jean Michel Halimi, et al.
Journal of Medical Economics|July 4, 2024
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and ItalyAnnabel Barrett, Kristina S Boye, Luis-Emilio García-Pérez, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
BMJ Open|January 29, 2026
Psychosocial burden in type 1 diabetes: a cross-sectional network analysis in the SFDT1 studyGloria A Aguayo, Vincent P Martin, Dulce Canha, et al.
Diabetes, Obesity & Metabolism|September 13, 2023
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomesFrancesco Giorgino, Bruno Guerci, Martin Füchtenbusch, et al.
BMJ (Clinical Research Ed.)|February 29, 2012
Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetesAndrew J Farmer, Rafael Perera, Alison Ward, et al.
Diabetes, Obesity & Metabolism|March 10, 2026
Economic burden of type 2 diabetes management in France according to clinical characteristicsBruno Guerci, Christèle Blanc-Bisson, Eric Vicaut, et al.
Diabetes Care|May 26, 2016
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 TrialJulio Rosenstock, Bruno Guerci, Markolf Hanefeld, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 4, 2020
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported OutcomesKristina S Boye, Hélène Sapin, Luis-Emilio García-Pérez, et al.
Diabetes Technology & Therapeutics|April 8, 2011
A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patientsPauline Schaepelynck, Eric Renard, Nathalie Jeandidier, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 7, 2021
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline CharacteristicsLuis-Emilio García-Pérez, Kristina S Boye, Myriam Rosilio, et al.
Journal of Diabetes and Its Complications|May 17, 2017
Urinary lysophopholipids are increased in diabetic patients with nephropathyJean-Sébastien Saulnier-Blache, Eva Feigerlova, Jean Michel Halimi, et al.
Journal of Medical Economics|July 4, 2024
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and ItalyAnnabel Barrett, Kristina S Boye, Luis-Emilio García-Pérez, et al.
Pageof 12